Background

The esophagus (blue in figure) is a muscular tube that carries food from the back of the mouth (pharynx – green) to the stomach (red). Cancers that occur in this organ are often difficult to treat, in part because “alarm symptoms” such as difficulty swallowing (dysphagia) or bleeding often do not appear until the cancer is at a late stage. Unfortunately, less than half of persons with esophageal cancer survive  more than a year after diagnosis. Therefore, preventing the  cancer and detecting it at an early stage remain the most effective options for reducing mortality from the disease.

The esophagus is in blue.

Two histologic types of cancer typically occur in the esophagus. It  is normally lined by squamous cells, which can give rise to a type of cancer – esophageal squamous cell carcinoma (ESCC) –  occurring anywhere in the esophagus. Sometimes the squamous cell lining  can be transformed into columnar cells which are similar to the lining of the small intestine, in a process termed metaplasia. This usually  occurs under conditions of chronic gastroesophageal reflux (e.g., heartburn or acid regurgitation) and the resulting condition is termed Barrett’s esophagus. A second type of cancer – esophageal adenocarcinoma (EAC)  – typically arises in Barrett’s epithelium and usually develops within the lower one-third of the esophagus or at the junction with the stomach  (gastroesophageal junction.) EAC is the most common type of esophageal cancer in the U.S. and many western countries, while ESCC is the most common type worldwide.

Figure 1.

In 2018, an estimated 550,000 new cases of  esophageal  cancer (both types) occurred worldwide, making it the seventh most commonly occurring cancer and the sixth most common cause of cancer death.(1)

In less developed regions, ESCC is by far the most common histological type. Particularly high rates occur in parts of China, Central Asia and Eastern Africa (figure 1.) In contrast, the United States and much of Western Europe and Australia has seen a remarkable rise in the incidence of EAC which has transformed it from a relative rarity in the 1970s to the most common histological type of esophageal cancer in the U.S. today.(2–5)

Figure 2. EAC incindence in white males in U.S.

EAC is most common among white males, in whom incidence has  increased about 10-fold in the U.S. since the early 1970s (figure 2.)(6)  Incidence rates in other groups also have risen, although from a much lower baseline rate. Like many solid tumors, EAC incidence rises rapidly with age (figure 3, left graph.) Persons diagnosed with  Barrett’s  esophagus are substantially more likely (about 20-fold at 60  years of  age) to develop EAC than the general population (figure 3,  right graph.)(7)

Figure 3. Incidence of EAC in U.S. In the general population (left graph) EAC is much more common among white males at all ages. Persons with Barrett’s esophagus (right graph) are at substantially higher risk of developing EAC (note the very different scales) than in the general population.7

References:

1. Cancer today. Available at: http://gco.iarc.fr/today/home. (Accessed: 19th November 2018)

2. Hur, C. et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer119, 1149–58 (2013).

3. Islami, F., DeSantis, C. E.  & Jemal, A. Incidence Trends of Esophageal and Gastric Cancer  Subtypes by Race, Ethnicity, and Age in the United States, 1997-2014. Clin. Gastroenterol. Hepatol. (2018). doi:10.1016/j.cgh.2018.05.044

4. Malhotra, G. K. et al. Global trends in esophageal cancer. J. Surg. Oncol. 115, 564–579 (2017).

5. Xie, S.-H. & Lagergren, J. Risk factors for oesophageal cancer. Best Pract. Res. Clin. Gastroenterol. (2018). doi:10.1016/j.bpg.2018.11.008

6. Vaughan, T. L. & Fitzgerald, R. C. Precision prevention of oesophageal adenocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 12, 243–248 (2015).

7. Anon. IC-RISC. Available at: [https://ic-risc.fredhutch.org/].

About
This website contains a curated and opinionated look at recent literature regarding the epidemiology and prevention of esophageal cancer, with an emphasis on esophageal adenocarcinoma. It is developed by Thomas L Vaughan MD, MPH, who can be reached with questions or suggestions through email or his research website.
©2021 Thomas L Vaughan
Disclaimer
This website should not be considered, or used as a substitute for, medical advice, diagnosis or treatment. This site does not constitute the practice of any medical or other professional health care advice, diagnosis or treatment. The information on this website represent the views solely of Dr. Vaughan.
Privacy
Cookies are used to quantify website use for resource planning.  Complete IP addresses are not collected (i.e.,  203.0.113.123 will be  recorded as 203.0.113.??) Feel free to opt out of cookies using add-ins of your choice without affecting website function.  No user information is collected by the risk calculator (IC-RISC).